Alexion Pharmaceuticals I... (ALXN)
Alexion Pharmaceuticals Statistics
Share Statistics
Alexion Pharmaceuticals has 0 shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 0 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 56.73 and the forward PE ratio is null. Alexion Pharmaceuticals's PEG ratio is -0.76.
| PE Ratio | 56.73 |
| Forward PE | n/a |
| PS Ratio | 5.64 |
| Forward PS | null |
| PB Ratio | 2.94 |
| P/FCF Ratio | 11.82 |
| PEG Ratio | -0.76 |
Enterprise Valuation
Alexion Pharmaceuticals has an Enterprise Value (EV) of 33.83B.
| EV / Sales | 5.57 |
| EV / EBITDA | 33.73 |
| EV / EBIT | 11.27 |
| EV / FCF | 11.68 |
Financial Position
The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.22.
| Current Ratio | 3.59 |
| Quick Ratio | 3.11 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 2.55 |
| Debt / FCF | 0.88 |
| Interest Coverage | 27.32 |
Financial Efficiency
Return on Equity is 5.18% and Return on Invested Capital is 21.34%.
| Return on Equity | 5.18% |
| Return on Assets | 3.33% |
| Return on Invested Capital | 21.34% |
| Revenue Per Employee | $1.58M |
| Profits Per Employee | $157.26K |
| Employee Count | 3,837 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.71 |
Taxes
| Income Tax | -34.4M |
| Effective Tax Rate | -6.05% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 1.26, so Alexion Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | null |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | null |
| Average Volume (20 Days) | 4.22M |
Income Statement
In the last 12 months, Alexion Pharmaceuticals had revenue of 6.07B and earned 603.4M in profits. Earnings per share was 2.75.
| Revenue | 6.07B |
| Gross Profit | 5.52B |
| Operating Income | 2.86B |
| Net Income | 603.4M |
| EBITDA | 1B |
| EBIT | 673.7M |
| Earnings Per Share (EPS) | 2.75 |
Balance Sheet
The company has 2.96B in cash and 2.56B in debt, giving a net cash position of 402.5M.
| Cash & Cash Equivalents | 2.96B |
| Total Debt | 2.56B |
| Net Cash | 402.5M |
| Retained Earnings | 5.24B |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was 3B and capital expenditures -106.7M, giving a free cash flow of 2.9B.
| Operating Cash Flow | 3B |
| Capital Expenditures | -106.7M |
| Free Cash Flow | 2.9B |
| FCF Per Share | 13.22 |
Margins
Gross margin is 90.88%, with operating and profit margins of 47.12% and 9.94%.
| Gross Margin | 90.88% |
| Operating Margin | 47.12% |
| Pretax Margin | 9.37% |
| Profit Margin | 9.94% |
| EBITDA Margin | 16.53% |
| EBIT Margin | 47.12% |
| FCF Margin | 47.71% |
Dividends & Yields
ALXN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.76% |
| FCF Yield | 8.46% |
Analyst Forecast
Currently there are no analyst rating for ALXN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 23, 2011. It was a forward split with a ratio of 2:1.
| Last Split Date | May 23, 2011 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |